NeuBase Therapeutics, Inc.
neubasetherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 9, 2023. Its latest SEC filing is a 15-12G from Jan 13, 2025.
10-Q for Q3 FY2023, filed Nov 9, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops genetic medicines designed to target disease-causing genes for patients with rare diseases, cancers and other disorders.
10-K for FY2022, filed Dec 21, 2022NeuBase Therapeutics, Inc. (“NeuBase”,“Company”, “we”, “us” and “our”) is a biotechnology company focused on significantly reducing the…View ↗
We have designed, built, and validated a new technology platform that can uniquely Drug the Genome™ to address the three disease-causing…View ↗
We are developing precision genetic medicines targeting rare, monogenic diseases for which there are no approved therapies, as well as more…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 9, 2023
−$1.8MView ↗
- ▼ −76% (Loss)
- vs −$7.6M in Q3 FY2022
-
Jan 7, 2025
Sets an initial stockholder distribution under its dissolution plan
The initial distribution is approximately $500,000; Todd P. Branning also resigned as interim chief executive and chief financial officer.
Sources
8-K, filed Jan 7, 2025
On January 2, 2025, the Board approved and adopted a Plan of Distribution (the “Plan of Distribution”) in accordance with the Company’s…View ↗
-
Jun 27, 2024
Files a certificate of dissolution
The filing took effect immediately and begins the process of settling the company’s affairs and distributing remaining assets.
Sources
8-K, filed Jun 27, 2024
On June 26, 2024, NeuBase Therapeutics, Inc. (the “Company”) filed a Certificate of Dissolution with the Secretary of State of the State of…View ↗
-
May 3, 2024
Expects Nasdaq suspension and delisting
The company did not regain the minimum bid-price requirement and said it would not appeal.
Sources
8-K, filed May 3, 2024
On May 2, 2024, the Staff notified the Company that it has not regained compliance with the Minimum Bid Price Requirement (the “Delisting…View ↗
Broader target and platform focus
The older report describes PATrOL as antisense therapies that bind mutant RNA; the latest describes compounds that can directly engage the genome and adds gene editing to the platform’s focus.
10-K for FY2019, filed Jan 10, 2020 10-K for FY2022, filed Dec 21, 2022
Who Did They Compete With?
Competes with Arbor Biotechnologies, Beam Therapeutics, bluebird bio, Caribou Biosciences, Chroma Medicine, CRISPR Therapeutics, Editas Medicine, Graphite Bio., Intellia Therapeutics, Mammoth Biosciences, Metagenomi, Precision Biosciences, Prime Medicine, Sangamo Therapeutics, Scribe Therapeutics, Tune Therapeutics, Verve Therapeutics, Avidity Biosciences, Dyne Therapeutics, and Design Therapeutics
10-K for FY2022, filed Dec 21, 2022The field of gene editing is broad and characterized by a diversity of approaches. These include but are not limited to: CRISPR/Cas9…View ↗
Loading...
